作者
R Adam, V Delvart, V Karam, C Ducerf, F Navarro, C Letoublon, J Belghiti, D Pezet, D Castaing, YP Le Treut, J Gugenheim, P Bachellier, Jacques Pirenne, P Muiesan, European Liver, Intestine Transplant Association
发表日期
2015/2/1
期刊
American Journal of Transplantation
卷号
15
期号
2
页码范围
395-406
出版商
Elsevier
简介
Between 2003 and 2012, 42 869 first liver transplantations performed in Europe with the use of either University of Wisconsin solution (UW; N = 24 562), histidine-tryptophan-ketoglutarate(HTK; N = 8696), Celsior solution (CE; N = 7756) or Institute Georges Lopez preservation solution (IGL-1; N = 1855) preserved grafts. Alternative solutions to the UW were increasingly used during the last decade. Overall, 3-year graft survival was higher with UW, IGL-1 and CE (75%, 75% and 73%, respectively), compared to the HTK (69%) (p < 0.0001). The same trend was observed with a total ischemia time (TIT) >12 h or grafts used for patients with cancer (p < 0.0001). For partial grafts, 3-year graft survival was 89% for IGL-1, 67% for UW, 68% for CE and 64% for HTK (p = 0.009). Multivariate analysis identified HTK as an independent factor of graft loss, with recipient HIV (+), donor age ≥65 years, recipient HCV (+), main disease …
引用总数
20152016201720182019202020212022202320245121819916151352